@EzequielZaidel @DrPontecarlosi @mencardio @CardiologiaSVC @SIAC_cardio @SVMI_Nacional @svinfectologia @rigotordoc @ernestocardio @emartinezgmg @adribaran @torresviera @fernando_wyss Ezequiel, no lo hay por ahora, pero q opinión tenes de aquellos pacientes
MARINER Substudy a propósito de #COVID19 N=9.822 Post-alta x Patologías Médicas Ag hasta 45 d Rivarox 10 mg OD vs Placebo PFP (TEV, IM, Ictus isq & Muerte CV) Riva 1,28% vs Pla 1,77% p=0,049 Sangrado Mayor Riv 0,27% vs Pla 0,18% p=0,398 https://t.co/I
ちょっと今日はこれで最後にしておきます。 退院後の抗凝固継続というコンセプト Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Th... https://t.co/ZP8GyGElvt Editorialで色々難しさについてふれているのは面白いです https://t.co/IYMIRnpghN #Cardiojapan
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients | JACC https://t.co/l3o5A5csnm https://t.co/wlVMbtwJKM
Post discharge prophylaxis with Rivaroxaban in critically ill medical patient. (NB CI upper limit is at 1!!) https://t.co/0A9KqO7vo7
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients MARINER - 28% reduction in fatal and major thromboembolic events without a significant increase in major bleeding. https://t.co/hopous2m4H
RT @hayder_aldiwani: Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients |…
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients | JACC: Journal of the American College of Cardiology. Thanks @DrSuzanMahdai for sharing this. Worth reading https://t.co/My0UHdkcjJ
RT @bernardowise: Taking 10-mg rivaroxaban for 45 days post-discharge of #CoVid19 reduced fatal and major events by a relative 28% (1.28% v…
Prophylactic anticoagulation post-discharge: To be continued? https://t.co/lQtlAdjcUZ Shared from Epocrates, The #1 medical reference app. https://t.co/6B3jbzYYWk https://t.co/j4hS3DrWYg
Prophylactic anticoagulation post-discharge: To be continued? https://t.co/lQtlAdjcUZ Shared from Epocrates, The #1 medical reference app. https://t.co/6B3jbzYYWk https://t.co/KxfbcAdljh
Prophylactic anticoagulation post-discharge: To be continued? https://t.co/lQtlAdjcUZ Shared from Epocrates, The #1 medical reference app. https://t.co/6B3jbzYYWk https://t.co/ipbS3dNW9a
Journal club ideas? @DWallaceMD @jenreadlynn @ValerieLang9 @UR_HMD_FD I have yet be able to find clear definitions for “medically ill”
RT @Manugrillo2: Post-Discharge Prophylaxis With #Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients https…
RT @Manugrillo2: Post-Discharge Prophylaxis With #Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients https…
RT @Manugrillo2: Post-Discharge Prophylaxis With #Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients https…
Post-Discharge Prophylaxis With #Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients https://t.co/b0bglKLnnQ
Taking 10-mg rivaroxaban for 45 days post-discharge of #CoVid19 reduced fatal and major events by a relative 28% (1.28% v. 1.77%, HR: 0.72; 95% CI: 0.52.1.0; p 0.049) in pts with additional risk factors for VTE. https://t.co/P6AidGiQf8
RT @preopconsult: Analysis of secondary endpoint in MARINER shows efficacy and safety of 10mg rivaroxaban (7.5 mg for renally impaired was…
RT @preopconsult: Analysis of secondary endpoint in MARINER shows efficacy and safety of 10mg rivaroxaban (7.5 mg for renally impaired was…
RT @AlexSpyropoul: New data on reducing arterial events with extended thromboprophylaxis in medical patients: https://t.co/jsEbubNLAr #WTDa…
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients | JACC: Journal of the American College of Cardiology https://t.co/suEVKvbJjN
RT @AlexSpyropoul: New data on reducing arterial events with extended thromboprophylaxis in medical patients: https://t.co/jsEbubNLAr #WTDa…
RT @AlexSpyropoul: New data on reducing arterial events with extended thromboprophylaxis in medical patients: https://t.co/jsEbubNLAr #WTDa…
RT @AlexSpyropoul: New data on reducing arterial events with extended thromboprophylaxis in medical patients: https://t.co/jsEbubNLAr #WTDa…
Analysis of secondary endpoint in MARINER shows efficacy and safety of 10mg rivaroxaban (7.5 mg for renally impaired was not effective) Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients htt
RT @AlexSpyropoul: New data on reducing arterial events with extended thromboprophylaxis in medical patients: https://t.co/jsEbubNLAr #WTDa…
塞栓リスクの高い急性の内科疾患患者では、退院後もDOACは継続したほうがいい。https://t.co/RvKidBuLYL https://t.co/KJnLktO6Dz
New data on reducing arterial events with extended thromboprophylaxis in medical patients: https://t.co/jsEbubNLAr #WTDay20 #isth #ZuckerSOM #Canvector #Cardiotwitter #thrombosis #EuropeanTHA #ClotChat @NATFthrombosis
内科の急性疾患で塞栓リスクが高いと判断された患者では、退院後もDOACを継続したほうがいい。 https://t.co/RvKidBdb7d https://t.co/ZItnFZJkBt